Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.31 |
| ▸ | CTSK | P43235 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL916073 | 1.00 | KMT2A (0.37) | KMT2ATDP1KCNA5CTSKSMN1; SMN2 | |
| SCHEMBL916177 | 0.88 | KMT2A (0.38) | KMT2ATDP1KCNA5CTSK | |
| SCHEMBL916175 | 0.88 | KMT2A (0.38) | KMT2ATDP1KCNA5CTSK | |
| SCHEMBL915022 | 0.88 | KMT2A (0.38) | KMT2ATDP1KCNA5CTSK | |
| SCHEMBL915343 | 0.88 | KMT2A (0.38) | KMT2ATDP1KCNA5CTSK | |
| SCHEMBL3264354 | 0.88 | KMT2A (0.38) | KMT2ATDP1KCNA5CTSK | |
| SCHEMBL915345 | 0.88 | KMT2A (0.38) | KMT2ATDP1KCNA5CTSK | |
| SCHEMBL4696406 | 0.87 | KMT2A (0.49) | KMT2ATDP1SMN1; SMN2MEN1 | |
| SCHEMBL914977 | 0.87 | KMT2A (0.49) | KMT2ATDP1SMN1; SMN2MEN1 | |
| SCHEMBL914978 | 0.87 | KMT2A (0.49) | KMT2ATDP1SMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1919859-B1 | ACYLOXYALKYL CARBAMATE PRODRUGS OF TRANEXAMIC ACID AND USE | XENOPORT INC (US) | 2010-06-02 | — | — | EP | claimed |
| US-8372881-B2 | Acyloxyalkyl carbamate prodrugs of tranexamic acid, methods of synthesis and use | XENOPORT, INC. (US) | 2013-02-12 | — | — | US | disclosed |
| US-20110009483-A1 | ACYLOXYALKYL CARBAMATE PRODRUGS OF TRANEXAMIC ACID, METHODS OF SYNTHESIS AND USE | XENOPORT, INC. (US) | 2011-01-13 | — | — | US | disclosed |
| US-7777070-B2 | Acyloxyalkyl carbamate prodrugs of tranexamic acid, methods of synthesis and use | XENOPORT, INC. (US) | 2010-08-17 | — | — | US | disclosed |
| EP-1919859-B1 | ACYLOXYALKYL CARBAMATE PRODRUGS OF TRANEXAMIC ACID AND USE | XENOPORT INC (US) | 2010-06-02 | — | — | EP | disclosed |
| US-20100036148-A1 | Acyloxyalkyl Carbamate Prodrugs of Tranexamic Acid, Methods of Synthesis and Use | XENOPORT, INC. (US) | 2010-02-11 | — | — | US | disclosed |
| US-7592369-B2 | Acyloxyalkyl carbamate prodrugs of tranexamic acid, methods of synthesis and use | XENOPORT, INC. (US) | 2009-09-22 | — | — | US | disclosed |
| US-20080153898-A1 | ACYLOXYALKYL CARBAMATE PRODRUGS OF TRANEXAMIC ACID, METHODS OF SYNTHESIS AND USE | XENOPORT, INC. | 2008-06-26 | — | — | US | disclosed |
| US-7351740-B2 | Acyloxyalkyl carbamate prodrugs of tranexamic acid, methods of synthesis and use | XENOPORT, INC. (US) | 2008-04-01 | — | — | US | disclosed |
| US-20070027210-A1 | Acyloxyalkyl carbamate prodrugs of tranexamic acid, methods of synthesis and use | XENOPORT, INC. | 2007-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027210-A1 | Acyloxyalkyl carbamate prodrugs of tranexamic acid, methods of synthesis and use | ACMSD, APEH, CPS1 | KMT2A 1530/4885TDP1 1931/4885KCNA5 3241/4885 |
| US-20110009483-A1 | ACYLOXYALKYL CARBAMATE PRODRUGS OF TRANEXAMIC ACID, METHODS OF SYNTHESIS AND USE | ACMSD, APEH, CPS1 | KMT2A 1530/4885TDP1 1931/4885KCNA5 3241/4885 |
| US-20080153898-A1 | ACYLOXYALKYL CARBAMATE PRODRUGS OF TRANEXAMIC ACID, METHODS OF SYNTHESIS AND USE | ACMSD, APEH, CPS1 | KMT2A 1530/4885TDP1 1931/4885KCNA5 3241/4885 |
| US-20100036148-A1 | Acyloxyalkyl Carbamate Prodrugs of Tranexamic Acid, Methods of Synthesis and Use | ACMSD, APEH, CPS1 | KMT2A 1530/4885TDP1 1931/4885KCNA5 3241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.